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Abstract
Spinocerebellar ataxia type 2 is a polyglutamine (polyQ) disease associated with an expanded polyQ domain within the
protein product of the ATXN2 gene. Interestingly, polyQ repeat expansions in ATXN2 are also associated with amyotrophic
lateral sclerosis (ALS) and parkinsonism depending upon the length of the polyQ repeat expansion. The sequence encoding
the polyQ repeat also varies with disease presentation: a pure CAG repeat is associated with SCA2, whereas the CAG repeat
in ALS and parkinsonism is typically interrupted with the glutamine encoding CAA codon. Here, we asked if the purity of
the CAG sequence encoding the polyQ repeat in ATXN2 could impact the toxicity of the ataxin-2 protein in vivo in Drosophila.
We found that ataxin-2 encoded by a pure CAG repeat conferred toxicity in the retina and nervous system, whereas ataxin-2
encoded by a CAA-interrupted repeat or CAA-only repeat failed to confer toxicity, despite expression of the protein at
similar levels. Furthermore, the CAG-encoded ataxin-2 protein aggregated in the fly eye, while ataxin-2 encoded by either a
CAA/G or CAA repeat remained diffuse. The toxicity of the CAG-encoded ataxin-2 protein was also sensitive to the
translation factor eIF4H, a known modifier of the toxic GGGGCC repeat in flies. These data indicate that ataxin-2 encoded by
a pure CAG versus interrupted CAA/G polyQ repeat domain is associated with differential toxicity, indicating that
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Introduction
Expansions of microsatellite repeats are a cause of several neu-
rodegenerative disorders. A notable example is the polyglu-
tamine (polyQ) diseases, which are caused by an expansion of a
glutamine-encoding CAG-repeat in the respective disease genes,
and includes six spinocerebellar ataxias (SCA1, 2, 3, 6, 7 and 17),
Huntington’s disease and dentatorubral pallidoluysian atrophy
(1,2). Despite the CAG-repeat mutations occurring in a diverse
set of proteins, the polyQ diseases share some key patholog-
ical mechanisms. For example, longer CAG-repeat expansions
result in earlier disease onset and more severe symptoms (2).
Furthermore, an expanded polyQ results in aggregation of the
disease protein, which causes toxicity via gain-of-function and
loss-of-function effects (1,2). An additional mechanism shared
by many of the diseases caused by expansions of microsatellites
(e.g. CAG, CTG and GGGGCC expansions) is toxicity induced
by the structure of the expanded RNA (3–5). RNA toxicity, first
implicated in myotonic dystrophy type 1, can lead to effects by
binding to and sequestering key cellular RNA-binding proteins
such as splicing factors (6–8). RNA with expanded repeats can
also bind to translation factors and in doing so, the RNA primes
repeat-associated non-AUG protein translation (RAN), which can
occur in multiple reading frames and generates peptides (e.g.
poly-glutamine, poly-serine and poly-alanine) that accumulate
in the brain and are toxic to cells (9–15). Although it is known
that the CAG-repeat from SCA2, SCA3 and Huntington’s disease
can give rise to toxicity when the repeat is either isolated or
flanked by short regions of coding sequence (12,16,17), less is
known about the RNA-toxicity that arises from the CAG-repeat
when embedded in the entire transcript.
The gene encoding the ataxin-2 protein (ATXN2) harbors a
CAG-repeat that normally consists of 22 or 23 repeats interrupted
with two glutamine-encoding CAA codons (18–20). Expansion
of the CAG-repeat in ATXN2 to >33 causes SCA2, an adult-
onset ataxia that primarily affects neurons in the cerebellum
and brainstem (2,21). The disease-causing repeat in SCA2 is a
pure CAG-tract and lacks the CAA interruption observed in the
normal allele (18–20). Protein toxicity is thought to occur in SCA2
as evidenced by the aggregation of polyQ-expanded ataxin-2
protein in the cytoplasm of affected neurons (22,23). The ataxin-
2 protein functions in translation and RNA metabolism (2,24,25).
A key RNA-binding protein modulated by ataxin-2 is TDP-43
(26). TDP-43 is central to the motor neuron disease amyotrophic
lateral sclerosis (ALS) and is mislocalized to the cytoplasm of
motor neurons in >95% of patients with ALS (27). In animal and
cellular models, ataxin-2 is a dose-sensitive modifier of TDP-43
whereby upregulation of ataxin-2 promotes TDP-43 neurotoxi-
city and downregulation of ataxin-2 mitigates TDP-43-induced
toxicity (26,28,29). Thus, the function of ataxin-2 appears crucial
to additional disease contexts.
Clinical, pathological and genetic evidence suggests that
SCA2 may be on a disease spectrum with parkinsonism and
ALS. For example, some patients harboring an SCA2 expansion
can present with parkinsonism or motor neuron disease (30–
35). Cytoplasmic accumulation of the ALS protein TDP-43 has
been observed in SCA2 brain tissue (26), suggesting that the
degeneration in SCA2 and ALS may impact similar cellular
pathways. Furthermore, intermediate polyQ expansions of ∼32–
35Q are associated with parkinsonism (36) and ∼29–33Q are
associated with ALS (26,37,38). Intriguingly, and in contrast to
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Figure 1. Ataxin-2 with different RNA sequences of the polyQ repeat region. (A) Domain structure of ataxin-2 protein. PolyQ: polyglutamine domain, LSm: like-Sm
domain, LSmAD: LSm associated domain and PAM2: PolyA-binding protein interacting motif. (B) Predicted RNAfold structure of the ataxin-2 RNA with different CAG
purity polyQ repeat sequences. The red arrows indicate the CAG, CAA/G or CAA tract in the mRNA sequence, blue arrows indicate regions outside of the repeat that are
altered by the CAA/G or CAA expansion.
associated with ALS and parkinsonism is often interrupted with
CAA codons (39,40). Why the subtle differences in CAG/polyQ-
repeat length and composition can lead to different disease
presentations is unclear. Elucidating the disease mechanisms
that underlie the different CAG repeats will be key for under-
standing the biological features that contribute to differences in
neuronal vulnerability and disease presentation.
To better understand how the composition of the CAG-
repeats impact ATXN2-associated toxicity, we developed
Drosophila that were transgenic for the human ataxin-2 protein
encoded by either a pure CAG repeat, a CAG-repeat interrupted
with CAA (CAA/G) or by the extreme non-CAG repeat of a pure
CAA sequence. Surprisingly, our data indicate that ataxin-2
expressed from a pure CAG repeat confers toxicity in ways that
ataxin-2 expressed from a CAA/G interrupted repeat or pure CAA
repeat does not, suggesting that RNA toxicity is a component of
the ataxin-2 CAG-repeat expansion. Our novel ataxin-2 fly model
presents a highly manipulable genetic system to dissect toxic
mechanisms associated with a pure CAG repeat in the context
of the ataxin-2 protein.
Results
Transgenic constructs of ataxin-2 with different polyQ
DNA sequences
To explore the possibility that alternative disease-causing mech-
anisms are associated with different types of repeats encod-
ing polyQ, we generated a series of constructs and transgenic
Drosophila that encoded human ATXN2 with either a pure CAG
repeat, an interrupted CAA/G repeat or a pure CAA repeat (Fig. 1).
Our overall approach was to assess the toxicity and degeneration
that arises from the different ataxin-2 proteins when they are
selectively expressed in the Drosophila eye. Our previous data
indicated that shorter repeat expansions in ATXN2 (CAG22 or
CAG32) confer little or no visible effects on the eye (28). In human
disease, the CAG-repeat length in SCA2 is in the range of 35–
59, but it can be as long as 77 repeats (18–20,41). Given that
CAG-repeat length in ATXN2 negatively correlates with disease
severity, we assessed the effect of a CAG-repeat of 64 units in the
context of the human ataxin-2 protein.
We designed constructs encoding human ataxin-2 with
either a pure-CAG repeat of 64 units in length, a CAG repeat
interrupted with CAA (CAA/G) in a pattern seen in ALS patients
(40), or with the extreme of a pure CAA repeat. Structurally,
RNAs with a pure CAG repeat fold into a hairpin, whereas CAA-
interrupted repeats break the hairpin and take on a different
structure (42). To gain insight into the structures that the
different CAG repeat regions (CAG, CAA/G and CAA) are predicted
to take in the context of the ATXN2 mRNA, we used the RNAfold
webserver (43). This showed that the expanded CAG, CAA/G and
CAA repeat sequences in the ATXN2 mRNA are predicted to
undertake very different structures (Fig. 1B): as expected, the
pure CAG is a predicted hairpin, whereas the CAA/G repeat
is a series of smaller hairpins, while the CAA forms a large
loop (Fig. 1B). Thus, within the context of the entire ATXN2
mRNA sequence, the CAA/G and CAA repeats cause predicted
differences in the structure of the larger transcript.
A series of transgenic Drosophila strains
expressing ataxin-2 bearing different polyQ
codon repeat sequences
To measure and compare disease-causing toxicity of human
ATXN2 with an expanded CAG versus CAA/G versus CAA repeat,
we generated approximately 10 independent strains of trans-
genic Drosophila (also referred to as the fly) for each repeat type.
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Figure 2. mRNA levels of UAS-ATXN2 transgenes. ATXN2 mRNA levels were
measured relative to ATXN2-CAG22 by real-time PCR. The ATXN2 transgenic
lines were expressed by the inducible daughterless gene switch (daGS)-GAL4
driver. Males of the correct genotype were aged for 48 h on 200 μg of RU486, at
25◦C. The abdomens were removed and discarded, and total RNA was isolated
from the remaining thorax and head tissue from ∼10 males per genotype. Data
represent the mean (s.e.m) from three independent cohorts. The transgenic lines
are grouped by ATXN2 mRNA expression levels (1×, 2× and 6×) relative to the
ATXN2-CAG22 mRNA levels. One-way ANOVA with Tukey’s test was performed
between repeat length groups. See Supplementary Material, Table S4 for full
genotypes.
DNA sequencing of the genomic DNA. The ATXN2 mRNA expres-
sion levels were measured by real-time PCR and compared with
our previously generated ATXN2-CAG22 fly line (28). This yielded
a series of fly lines with specific repeat lengths for each of the
distinct repeat sequences and with expression that was equal
to twice as high or up to six times greater than ATXN2-CAG22
(Fig. 2, Supplementary Material, Fig. S1, Supplementary Material,
Table S1). The pure CAG-repeat lines and pure-CAA lines had
lengths of 64 units and will be referred to as CAG64 and CAA64,
respectively, whereas the CAA/G repeat lines had a unit length of
65 and is referred to as CAA/G65. We selected transgenic ATXN2
fly lines of the different repeat structures and grouped them
into those with expression levels comparable to ATXN2-CAG22
(1×) or levels that were either 2-fold (2×) or 6-fold (6×) greater
than ATXN2-CAG22 (Fig. 2, Supplementary Material, Table S1).
Our selected ATXN2 transgenes (1×, 2× and 6×) were
expressed in the fly eye with gmr-GAL4 and the resulting effect
on the eye was assessed both externally and internally. Our
analysis showed that ATXN2 expressed at lower levels (1× and
2×) did not confer a visible effect on the external eye surface
or internal retina (Fig. 3). However, ATXN2-CAG64 (line HZ96R)
with expression 6× that of ATXN2-CAG22 (referred to as 6×
ATXN2-CAG64) caused external eye disruption with mild loss
of pigmentation and internal thinning of the retina (Fig. 3).
Intriguingly, expression of either ATXN2-CAA/G65 or ATXN2-
CAA64 with expression 6× that of ATXN2-CAG22 (referred to as 6×
ATXN2-CAA/G65 and 6× ATXN2-CAA64) failed to confer a visible
effect on the eye (Fig. 3). Thus, we selected the 6× ATXN2 fly
lines to investigate potential differences between a CAG, CAA/G
and CAA encoded repeat expansion.
A pure CAG-repeat is required for toxicity of ataxin-2
in the fly eye
Our initial analysis indicated that only the 6× ATXN2-CAG64
line conferred retinal degeneration. We examined this in greater
detail by quantifying the eye degeneration caused by expression
of the 6× ATXN2-CAG64 transgene compared with the 6× ATXN2-
CAA/G65 and 6× ATXN2-CAA64 transgenes. Our analysis showed
that expression of the 6× ATXN2-CAG64 transgene resulted in
a significant decrease (P < 0.0001) in retinal width, indicating
degeneration (Fig. 4A and B). In contrast, expression of the 6×
ATXN2-CAA/G65 and 6× ATXN2-CAA64 transgenes caused lit-
tle to no retinal degeneration (Fig. 4A and B). To confirm that
expression of ATXN2-CAG64 at a level of 6× the ATXN2-CAG22
line conferred toxicity, we expressed a combination of multiple
independent ATXN2-CAG64 transgenic lines in the eye, which
combined would be 6× ATXN2-CAG22, and confirmed both exter-
nal and internal degeneration of the fly eye (Supplementary
Material, Fig. S2). These data indicate that the degeneration of
the fly eye is due to expression of ATXN2-CAG64 at a level that is
6× ATXN2-CAG22.
We next considered that the different ATXN2 transgenic lines,
despite similar mRNA expression levels (see Fig. 2), may be trans-
lated to different extents, and perhaps, the 6× ATXN2-CAG64 fly
line had higher levels of the ataxin-2 protein compared with the
6× ATXN2-CAA/G65 and 6× ATXN2-CAA64 fly lines. To examine
this possibility, we assessed the levels of the ataxin-2 protein in
fly heads by western immunoblot. These data showed that the
level of ataxin-2 protein expressed from the 6× ATXN2-CAG64 and
6× ATXN2-CAA/G65 transgene did not significantly differ and,
consistent with our mRNA analysis in Figure 2, both were higher
than ATXN2-CAG22 (4 ± 2 fold and 3 ± 2 fold (SD), respectively)
(Fig. 4C and D). However, strikingly, despite conferring no toxicity
when expressed in the fly eye (Fig. 4A and B), the level of ataxin-2
protein expressed by the 6× ATXN2-CAA64 line was significantly
higher than the ataxin-2 protein expressed by ATXN2-CAG22, 6×
ATXN2-CAG64 and 6× ATXN2-CAA/G64 (Fig. 4C and D). Thus, our
data suggest that the toxicity associated with ataxin-2 is not
simply due to expression levels of an ataxin-2 protein with a long
polyQ Q64/Q65 domain but is also due to the presence of a pure
and expanded CAG repeat sequence in the ATXN2 mRNA.
To further explore the differences in the ataxin-2 protein
produced by the different ATXN2 transgenes, we examined
ataxin-2 protein localization in fly retinal tissue. This revealed
that ataxin-2 when expressed by the 6× ATXN2-CAG64 transgene
accumulated into punctate aggregates (Fig. 4E). In contrast,
ataxin-2 expressed from the 6× ATXN2-CAA/G65 (Fig. 4E), or
ATXN2-CAA64 transgene (Supplementary Material, Fig. S3)
showed a diffuse expression pattern. Collectively, our data
indicate that a CAG-repeat expansion in ATXN2 is more toxic
than the interrupted CAA/G-repeat and CAA-repeat and that the
ATXN2-CAG64 mRNA promotes the aggregation of the ataxin-
2 protein. Combined, our data suggest that at the levels and
duration of ataxin-2 expression used in our studies, RNA toxicity
is a component of the SCA2 mutation in ataxin-2.
Differential toxicity in the nervous system of CAG
versus CAA/G versus CAA ATXN2 transgenes
Our analyses in the Drosophila eye indicated that only the 6×
ATXN2-CAG64 transgene conferred toxicity when expressed in
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Figure 3. The effects in the eye of ataxin-2 bearing different polyQ repeat sequences. The ATXN2 transgenes were expressed selectively in the fly eye with the gmr-GAL4
driver and crosses were raised at 24◦C. The external eye (upper panel) and internal retina (lower panel) are presented. Under these conditions, only expression of 6×
ATXN2-CAG64 caused visible degeneration of the eye. The white hatched line (upper panel) encompasses the external degeneration and the black double headed arrows
(lower panel) indicate retinal width. Control (ctrl) is w; UAS-mCD8-GFP/+; gmr-GAL4/+. See Supplementary Material, Table S4 for full genotypes.
to determine if the differential toxicity of a pure CAG repeat
versus a CAA/G-repeat or a CAA repeat extended to other tissue
types. To do this, we expressed the ATXN2 transgenes in a
range of different fly tissues. To test the effect of the repeat
in the context of the nervous system, we expressed the ATXN2
transgenes with the elav3A-GAL4 driver, which expresses in all
neurons of the brain from early developmental stages through to
adulthood. Consistent with expression of the 6× ATXN2-CAG64
transgene conferring toxicity to the eye, expression of the 6×
ATXN2-CAG64 transgene selectively in neurons was highly toxic
and caused a developmental lethality that resulted in very few
progeny surviving to adulthood (Fig. 5A). The 6× ATXN2-CAA/G65
and 6× ATXN2-CAA64, as well as 3× ATXN2-CAA/G65 and 3×
ATXN2-CAA64 (Supplementary Material, Fig. S3), conferred little
or no toxicity when expressed in the nervous system (Fig. 5A).
Thus, the selective toxicity of the 6× ATXN2-CAG64 transgene to
the retina was a shared property with expression in the entire
nervous system. Next, we directed the expression of the ATXN2
transgenes ubiquitously in the animal from early development
using the daughterless (da)-GAL4 driver. Intriguingly, in this case,
expression of all three 6× ATXN2 transgenes (CAG64, CAA/G65
and CAA64) was toxic and led to developmental lethality that
resulted in no adult survivors (Fig. 5B). Furthermore, ubiquitous
expression of ATXN2-CAG22, ATXN2-CAG32 and the 1× expanded
repeat proteins (ATXN2-CAG64, ATXN2-CAA/G64 and ATXN2-
CAA64) also resulted in no adult survivors (Supplementary
Material, Table S2). These findings suggest that ataxin-2 toxicity
when expressed ubiquitously may be associated with the
ataxin-2 protein versus the specific mRNA sequence of the
polyQ domain.
The enhancement of TDP-43 toxicity by ataxin-2 is
mediated by the protein and not the mRNA
ALS patients with an intermediate CAA/G expansion in ATXN2
present with the pathological hallmark of cytoplasmic TDP-43
aggregates in affected neurons (40,44), indicating that mutation
in ATXN2 impacts ALS disease features. Furthermore, we
previously demonstrated that upregulation of ATXN2-CAG22 and
ATXN2-CAG32 in the fly enhances the toxicity of the wild-type
form of TDP-43 (28). We thus determined whether the ATXN2
transgenes with a longer CAG repeat length enhanced the
toxicity of the wild-type TDP-43 and whether the composition
of the repeat (CAG or CAA) altered the enhancement. We
selected ATXN2-CAG64 and ATXN2-CAA64 transgenes that
expressed ATXN2 mRNA at levels that did not significantly
differ from ATXN2-CAG22 and were classified as 1× (see Fig. 2,
Supplementary Material, Table S1). Co-expression of the ATXN2
transgenes with TDP-43 in the fly eye showed that the 1×
ATXN2-CAG64 and 1× ATXN2-CAA64 transgenes enhanced TDP-
43 degeneration of the external eye and internal retina in a
manner similar to that of ATXN2-CAG22 (Fig. 6A and B and
Supplementary Material, Fig. S4). These data are consistent with
our previous findings that the interaction between TDP-43 and
ataxin-2 with an intermediate CAG repeat is at the protein level
(26,28), indicating that the RNA sequence of the ataxin-2 repeat
appears not to influence the interaction with TDP-43. These data
suggest that RNA toxicity arising from the pure CAG-repeat in
ATXN2 is a feature of SCA2, but not ALS.
Regulation of ATXN2-CAG64 toxicity by proteins
involved in transcription and translation
Mounting evidence indicates that transcription of long-repeat
sequences, such as CAG and GGGGCC, in the context of
short fragments of coding sequence is dependent on specific
transcription factors (45–48). Furthermore, the transcribed
RNA-repeat sequence can initiate RAN translation to generate
peptides that are toxic (10–12,14,15,17,49). These findings
suggest that targeting pathways that can selectively inhibit the
transcription and translation of long repeat sequences may have
potential as a therapeutic approach. Given that a pure repeat
of CAG64 in the context of the full-length coding sequence for
ATXN2 (6× ATXN2-CAG64) conferred strong toxicity to the fly
eye, we considered that transcriptional and RAN translational
mechanisms linked to the CAG repeat may be involved.
Previously, we defined a number of gene modifiers important
for transcription of an expanded GGGGCC-repeat sequence
that is found in the C9ORF72 gene in ALS and frontotemporal
degeneration (FTD) (46,47). Those studies indicated that the DRB
Sensitivity Inducing Factor (DSIF) and polymerase-associated
factor 1 (PAF1) complex are important for transcription through
the highly structured GGGGCC-repeat region. The DSIF complex
has also been shown to be important for transcription of CAG
repeats in the context of the Huntington’s disease fragment
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Figure 4. Protein expression of the ATXN2 transgenes shows the CAA/G65 and CAA64 express robust protein yet are not toxic. (A) Expression of 6× ATXN2-CAG64 at
25◦C disrupted the external eye (upper panel) and internal retina (lower panel), while 6× ATXN2-CAA/G65 or 6× ATXN2-CAA64 did not cause any visible degeneration.
The white hatched line encompasses external degeneration, and the black double headed arrows indicate retinal width. Expression of 6× ATXN2-CAG64 at 25◦C is
more toxic than at 24◦C (Fig. 3). Control (Ctrl) is w; UAS-mCD8-GFP/+; gmr-GAL4/+. (B) Expression of 6× ATXN2-CAG64 in the eye significantly reduced retinal width
compared with the control. Mean (s.e.m.) is presented. Each data point represents one head where three independent sections were measured and averaged; this was
performed on three animals from three independent biological repeats. The averaged data from each animal examined are presented and were analyzed by one-way
ANOVA and Tukey’s test. NS: not significant. Asterisks, significant. ∗P < 0.05 and ∗∗∗∗P < 0.0001. Control (Ctrl) is w; UAS-mCD8-GFP/+; gmr-GAL4/+. (C) ATXN2-CAG22, 6×
ATXN2-CAG64, 6× ATXN2-CAA/G65 and 6× ATXN2-CAA64 were expressed by the inducible daGS-GAL4 driver. Males of the correct genotype were aged for 48 h on 2 μg of
RU486, at 25◦C. Protein was isolated from head tissue from 10 males per genotype. Upper panel is immunoblotted for ataxin-2, arrow indicates the full-length protein, ∗
indicates the previously reported cleavage product (22). Lower panel is the same immunoblot probed for Lamin C. Control (Ctrl) is w1118; +/+; +/+ (BL5905). (D) Ataxin-2
protein levels were quantified relative to Lamin C. 6× ATXN2-CAA64 total protein levels were significantly higher than the protein produced by 6× ATXN2-CAG64 and
6× ATXN2-CAA/G65. Mean (s.e.m.), n = 3, one-way ANOVA and Tukey’s test is presented. NS: not significant. Asterisks, significant. ∗P < 0.05, ∗∗P < 0.01 and ∗∗∗P < 0.001.
Control (Ctrl) is w1118; +/+; +/+ (BL5905). (E) Expression of 6× ATXN2-CAA/G65 in the eye with the gmr-GAL4 driver leads to diffuse protein localization in the retina
(arrowheads). In contrast, 6× ATXN2-CAG64 when expressed in the eye accumulates as aggregated inclusions (arrows). Control (Ctrl) is w; UAS-mCD8-GFP/+; gmr-GAL4/+.
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Figure 5. Differential tissue toxicity of ATXN2 transgenes. (A) The ATXN2 transgenes were expressed selectively in the nervous system with the elav3A-GAL4 driver.
The resulting progeny were scored for genotype and a ratio was calculated based on the expected Mendelian frequencies. Only ATXN2-CAG64 was toxic in the nervous
system. Mean (s.e.m.), n = 4 experiments, one-way ANOVA and Tukey’s test is presented. NS: not significant. Asterisks, significant. ∗∗∗P < 0.001. Control (Ctrl) is w;
elav3A-GAL4/UAS-mCD8-GFP; +/+. (B) Ubiquitous expression of the ATXN2 transgenes with daughterless-GAL4 (da-GAL4) is toxic regardless of the sequence composition
of the polyQ repeat. Flies were scored as viable (1) or completely inviable (0), each datapoint represents a biological repeat (n = 3 experiments). Data were analysed using
a Kruskal–Wallis test and a Dunn’s multiple comparison test. Control (Ctrl) is w; UAS-mCD8-GFP/+; da-GAL4/+. See Supplementary Material, Table S4 for full genotypes.
Figure 6. The ataxin-2 protein with a CAG or CAA encoded polyQ enhances TDP-43 toxicity. (A) The toxicity of TDP-43 on the external (upper panel) and internal (lower
panel) eye is enhanced by the co-expression of ATXN2-CAG22 and ATXN2-CAG32 seen by the degenerate eye and collapsed retina. TDP-43 toxicity in the external and
internal eye was equally enhanced by the co-expression of ATXN2-CAG64 or ATXN-CAA64. White hatched lines (upper panel) indicate external degeneration and double-
headed arrows (lower panel) indicate retinal width. Control is w; mCD8-GFP/+; gmr-GAL4/+. (B) Quantitation of the retinal depth confirms that all ATXN2 transgenes,
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Figure 7. Interactions between ATXN2-CAG64 and translation factors that modulate GGGGCC repeat toxicity. (A) ATXN2-CAG64 was co-expressed in the eye with either
inverted repeats or siRNAs (si) directed to a control (ctrl), the Paf1 complex (Spt4 or Paf1) or to potential RAN translation factors (eIF4B or eIF4H1). The effect of the
PAF1 complex or potential RAN translation factors on ATXN2-CAG64 toxicity and the resulting effect on toxicity was assessed in the external eye (white hatched line,
upper panel) and internal retina (double-headed arrow, lower panel). Control (ctrl) is w; gmr-GAL4/+. (B) Quantification of internal retinal width showed that only
downregulation of eIF4H1 and eIF4E3 significantly improvement retinal width compared with the control (ctrl). Mean (s.e.m.), one-way Anova and a Dunnett’s test.
∗∗∗P < 0.0001, ∗P < 0.05, ns not significant. Control (ctrl) is w; gmr-GAL4/+. See Supplementary Material, Table S4 for full genotypes.
To determine if the DSIF complex or the PAF1 complex reg-
ulated the toxicity of ATXN2-CAG64, we determined whether
the mis-regulation of two crucial components of each complex
(Spt4 and Paf1, respectively) altered the eye degeneration caused
by ATXN2-CAG64. These studies showed that downregulation
of either Spt4 or Paf1 had little to no effect on ATXN2-CAG64
associated eye toxicity (Fig. 7), despite their robust effects on the
GGGGCC repeat in the fly (46,47). These data indicate that the
DSIF and PAF1 transcriptional protein complexes do not impact
the toxicity of the expanded CAG repeat in the context of the
ataxin-2 mRNA.
We next addressed the involvement of RAN translation in
the observed toxicity arising from the 6× ATXN2-CAG64 trans-
gene. Previously, we discovered in the context of the GGGGCC-
expanded repeat, elongation factors eIF4B and eIF4H function
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repeat (49). We therefore determined whether either eIF4B or
eIF4H were critical for the eye toxicity generated by the CAG64
repeat in ATXN2. Our data indicated that reduction of eIF4B
or eIF4H had some effect to mitigate the toxicity of the 6×
ATXN2-CAG64 transgene (Fig. 7). These data raise the possibility
that disease-associated toxicity of the expanded CAG repeat in
the ATXN2 mRNA may involve translational mechanisms and
share some mechanistic overlap with RAN translation of the
non-coding GGGGCC repeat.
Discussion
Here, we have generated and characterized a range of novel
fly models of ataxin-2-associated neurodegenerative disease.
Our ataxin-2 transgenic fly models express a pathogenic polyQ
ataxin-2 protein encoded by different glutamine-coding codons:
the SCA2-associated CAG repeat, interrupted CAA/G repeat asso-
ciated with parkinsonism and ALS, or an experimentally pro-
duced pure CAA repeat. Altering the composition of the CAG
repeat is predicted to change the RNA structure, with only the
CAG repeat forming a long single hairpin (see Fig. 1). Strikingly,
only the transgene with a polyQ domain encoded by the pure
CAG-repeat showed a degenerative effect when expressed in the
eye or nervous system (see Figs 3–5). The difference was not due
to differing levels of the ataxin-2 protein since the transgene
with a CAA (ATXN2-CAA64) sequence showed significantly higher
levels of the protein than the ATXN2-CAG64 transgene. Further-
more, the interrupted ATXN2-CAA/G64 repeat transgene, which
is predicted to fold into multiple shorter hairpins, produced pro-
tein at levels no different to the ATXN2-CAG64 transgene yet still
conferred no toxicity in the eye or nervous system in our study
(see Figs 3–5). Intriguingly, the ataxin-2 protein, despite being
expressed at similar levels with the different repeat sequences,
showed an aggregated pattern of expression from the CAG-
encoded transgene, compared with the CAA/G or CAA trans-
genes (see Fig. 4). These findings indicate that abolishing the
long CAG hairpin (CAA repeat) or replacement of a long hairpin
with several shorter hairpins (CAA/G) is sufficient to prevent
disease-associated toxicity to the eye and nervous system of
the fly. All repeat variants (CAG, CAA/G and CAA) of ATXN2
were toxic when expressed in the entire animal (see Fig. 5)
indicating that the nervous system appears more sensitive to the
expanded CAG repeat bearing ATXN2 transgene. One potential
mechanism underling the CAG-induced toxicity may be that
a pure CAG could encode toxic proteins in alternative reading
frames through RAN translation or through frameshifting. Such
proteins may be more aggregation prone than ataxin-2, thus
leading to the protein aggregation that we observe with the
CAG-repeat encoded ataxin-2 protein. Our data indicate that
the toxicity of the 6× ATXN2-CAG64 transgene shows sensitivity
to the levels of a translation factor (eIF4H; see Fig. 7) that also
modulates the toxicity of a GR peptide from the GGGGCC repeat
(49). The RNA hairpin formed by a pure CAG repeat could also
convey toxic features, such as activating the dsRNA pathway,
among others (51–53). Collectively, these studies provide a novel
fly model for dissecting different pathogenic mechanisms of
ataxin-2-associated neurodegenerative disease.
The human ATXN2 gene has different nucleic
acid sequences of the polyQ domain and different
clinical manifestations
PolyQ repeat expansions in ataxin-2 are interesting in that
they are a risk for a number of different clinical presentations.
Uninterrupted CAG repeat expansions in ATXN2 (34 and greater)
present with SCA2, which is characterized by cerebellar dysfunc-
tion and ataxia (2,21,54,55). In contrast, expansions greater than
the normal 22/23, but typically below the threshold for SCA2
(>33), can present with the motor neuron disease ALS (26,38).
CAA interrupted repeat expansions of SCA2 length can present
with parkinsonism (36,56), which is a movement disorder
characterized by tremors and stiffness. Interrupted expansions
have also been associated with FTD (35). These different disease
presentations reflect the varying extent to which different brain
regions are affected, with differing penetrance of functional loss
in different brain regions presumably underlying symptomatic
presentation of ataxia versus motor neuron degeneration versus
parkinsonism versus dementia as the dominant feature. Thus, a
fascinating aspect of these different ataxin-2-associated disease
presentations is that the domain encoding the polyQ is an
uninterrupted CAG repeat for SCA2, whereas ALS, parkinsonism
and FTD present with CAA interrupted CAG repeats (37,40,56).
For the polyQ diseases, the purity of the repeat influences its
tendency to expand both intergenerationally and somatically
(57–60). As a pure uninterrupted CAG repeat disease, SCA2 is
predicted to be associated with greater somatic expansions, and
thus a more toxic protein in tissues that bear the expansions.
In the fly, pure CAG repeats can expand intergenerationally,
although at a much lower frequency than in humans and
somatic expansion is extremely rare (61). Thus, the differing
toxicity of the 6× ATXN2-CAG64 in the fly is not likely due to
changes in the length of the repeat; rather, other biological
features associated with pure versus interrupted CAG repeats
likely underlie the differential toxicity seen in the fly.
Biological processes associated with pure versus
interrupted repeats
The structure of an RNA comprised of pure CAG repeats is a
hairpin (42,62). Such hairpins may sequester RNA-binding pro-
teins, leading to the loss of function of the sequestered protein
from other activities in the cell (5,63). In contrast, an RNA that is
CAA interrupted is predicted to undertake a branched structure
(see Fig. 1) and thus may not sequester proteins or not sequester
them to the same extent. The CUG-repeat expanded hairpin that
is associated with the myotonic dystrophy protein kinase has
been shown to activate signaling pathways (51,64), highlight-
ing another feature that may be associated with pure hairpin
repeats. Thus, by sequestering RNA-binding proteins and/or by
activating select pathways, the 6× ATXN2-CAG64 transgene may
be more toxic than an RNA expressed from a transgene bearing
an interrupted CAA/G-repeat RNA or the pure CAA-repeat RNA.
Pure CAG-repeat sequences, if sufficiently long, have the
capacity to frameshift (65,66) or to undergo RAN translation
(12,13,67). Thus, a long CAG repeat could frameshift or encode
poly-alanine (A) and poly-serine (S) protein. Both polyA and
polyS have been shown to be toxic to neurons in culture, and
potentially more toxic than polyQ (65,66). Previous studies with
an in vivo fly model for the intronic repeat expansion associated
with ALS/FTD of GGGGCC highlighted specific translation factors
that are important for expression of a poly-GR peptide (48,49).
Among these, eIF4B and eIF4H were key to GGGGCC toxicity
and importantly reducing their function on their own has little
effect on the animal. Here, we found that reduced expression of
eIF4B and eIF4H also mitigates toxicity of the 6× ATXN2-CAG64
transgene. These factors can stimulate the helicase activity of
eIF4A for translation of structured RNAs, indicative of a role in
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in mammalian cells that showed that RAN translation can occur
from an expanded CAG repeat that contained a short stretch
of the downstream ATXN2 sequence (17). Interestingly, here, we
found that the transcriptional regulator Spt4 appears not to
impact the toxicity of the expanded CAG repeat in the ATXN2
transgene, although it has been shown to be important for
transcription of pathogenic CAG-repeats in Huntington’s disease
transgenes and the GGGGCC repeat of ALS/FTD (45,46,50). We
also did not observe ATXN2-CAG64 to be sensitive to PAF1, a
transcription factor that impacts toxicity of the GGGGCC repeat
(47). These findings may indicate that in our ATXN2-CAG64 fly
model, RAN translation rather than repeat-associated transcrip-
tion, has a bigger influence on toxicity. Emerging data, including
this study, indicate some RAN translation factors are important
for more than one type of nucleotide repeat expansion, such
as GGGGCC, CGG and CAG-repeat expansions (14,15,49,68–71). A
fuller understanding of RAN translation is required to appreci-
ate the biological overlap between different repeat expansion
sequences.
Intriguingly, the 6× ATXN2-CAG64 was highly toxic in the
retina and nervous system compared with the interrupted
CAA/G repeat or CAA repeat; however, all transgenes were
equally toxic when expressed ubiquitously (see Figs 4 and 5).
These findings suggest that the brain and nervous system have
selective processes important for toxicity of a pure CAG repeat.
The similar toxicity observed for the three repeat types when
broadly expressed may be due to expression of ataxin-2 and
not processes associated with a pure CAG-repeat RNA encoding
the polyQ domain. Notably, the CAA- and CAG-repeat encoded
ATXN2 similarly enhanced TDP-43 (see Fig. 6), underscoring that
the interaction between TDP-43 and ataxin-2 is at the protein
level, and the CAG purity of the Ataxin-2 polyQ repeat has
minimal impact on this interaction.
Concluding remarks
We have uncovered a differential effect of a CAG-repeat encoded
ataxin-2 protein versus the same protein encoded by an inter-
rupted CAA/G repeat. Additional study of this system, including
for gene interactions and directed analysis to test mechanisms
(for example, mechanisms of RAN translation), may help to
uncover specific pathways and gene players that contribute to
the different clinical manifestations associated with the CAG
repeat composition in ATXN2 in human disease. These players
may also help reveal additional mechanisms associated with the
broader repeat expansion diseases.
Materials and Methods
Key reagents and sources are listed in Supplementary Material,
Table S4.
Drosophila culture and lines
Fly stocks were maintained on standard cornmeal molasses agar.
Progeny from fly crosses were raised at the indicated tempera-
tures. UAS-ATXN2(CAG)64, UAS-ATXN2 (CAA/G)65 and UAS-ATXN2
(CAA/G)64 transgenic lines were generated by The BestGene,
Inc (Chino Hills, CA). The control transgene was y1 w∗; UAS-
mCD8-GFP, which was obtained from the Bloomington Drosophila
Stock Center and backcrossed into w1118 (stock BL5905) with the
y1 removed from the genotype. The daughterless(da)-GAL4 was
obtained from Bloomington Drosophila Stock Center. Elav3A-Gal4
was a gift of M. Tanouye (72). Glass multimer reporter gmr-GAL4(III)
was a gift from Y. Hiromi. The UAS-TDP-43, UAS-ATXN2-Q22 and
UAS-ATXN2-Q32 are described (26,28). Sources and genotypes of
fly lines are given in Supplementary Material, Table S4. Experi-
mental crosses were carried out at 25◦C unless stated otherwise.
For all experimental crosses, the internal temperature of the
incubator was routinely monitored.
Ataxin-2 transgenes with variable sequence repeats
Transgenes expressing ATXN2 with a CAA/G interrupted repeat
were generated as follows. Two oligos were synthesized, 65caag-
1 and 65caag-2 (Supplementary Material, Table S3). Two PCR
reactions were set up using Phusion™ DNA polymerase (Ther-
moFisher Scientific, Waltham, MA) with pUAST-ATXN2-(CAG)22
as template, one with primer set NB1781 and 65caag-1 and the
second with primer set 65caag-2 and NB1792 (Supplementary
Material, Table S3). The PCR products were gel purified, phospho-
rylated with T4 polynucleotide Kinase (NEB M0201S) and ligated
with Quick ligation kit (Roche 11 635 379 001). A PCR reaction was
set up using Phusion DNA polymerase with the above ligation
reaction as template with primers NB1781 and NB1792. The
PCR product was gel purified, subcloned into the pGEMT vector
(Promega). The resulting colonies were prepared for sequencing
to determine the sequence and repeat length of the various
colonies. The clone with the desired repeat length was digested
with AcsI and XhoI, gel purified, ligated with pUAST-ATXN2
digested with AcsI/XhoI. The colonies were sequenced to confirm
the final construct pUAST-ATXN2-CAA/G65. The same strategy
was used to generate pUAST-ATXN2-CAA64, except using primers
CAA64-1A and CAA64-2S (Supplementary Material, Table S3).
pUAST-ATXN2-CAG64 made from a human ATXN2 clone with a
long polyQ repeat [generously shared by S. Pulst (University of
Utah, Salt Lake City, UT)], the final insert was sequence veri-
fied. The constructs were maxi-prepped and transformed into
Drosophila (The Best Gene, Inc., Chino Hills, CA). Independent
transgenic insertions were mapped and balanced to the chromo-
somes. To determine the repeat lengths in individual transgenic
fly lines, genomic DNA was isolated from single animals. PCR
was performed using primers Sca2-S2 and Sca2-B (Supplemen-
tary Material, Table S3) with Takara LA taq polymerase (Takara
RR02AG). The PCR products were run on a bioanalyzer to size
the repeat.
Realtime PCR
Approximately 10–20 males per genotype were aged on fly food
containing 200 μg of RU486 (Sigma-Aldrich, M8046) for 48 h.
Biological triplicates were collected for each genotype. RNA iso-
lation and real-time PCR were performed as previously described
(73), with minor alterations. The abdomen from the RU486-
treated males was removed and discarded, and the remaining
tissue from 10 males per genotype was homogenized by hand in
250 μl of Trizol (ThermoFisher Scientific, 15 596 026). After adding
an additional 250 μl Trizol, the RNA was extracted with chloro-
form and precipitated with ethanol and sodium acetate, pH 5.2.
RNA was re-suspended in RNase-free water. RNA quality was
assessed by Bioanalyzer. Genomic DNA was removed from the
total RNA using Turbo DNA-free (Amersham, AM1907). Random
primed cDNA was made from 250 μg of RNA using Superscript III
(ThermoFisher Scientific). Real-time PCR was performed using
SYBR FAST (Amersham 4 385 610), with all samples and repli-
cates run on the same 384-well plate. The Ct method was
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FP2, SV40 RP2, β-Tubulin FP and β-tubulin RP (Supplementary
Material, Table S3).
External eye microscopy, paraffin sectioning
and quantification
For external eye microscopy, three female flies were imaged
with a Leica Z16 Apo A microscope, DFC420 camera and 1.0×
planapochromatic objective (115× magnification and 0.117
numerical aperture) along with Leica Application Suite Montage
module software. For paraffin sections, fly heads were fixed
in Bouin’s solution (Sigma-Aldrich, HT10132) for 6d at RT and
then leached in 1 M Tris–HCl, pH 8.0 and 8.7% NaCl (Thermo
Fisher, 15 568–025) overnight. The tissue was incubated in a
series of ethanol washes each for 30 min with agitation (70%
EtOH, 90% EtOH, 95% EtOH, 95% EtOH, 100% EtOH, 100% EtOH),
incubated twice in xylene for 1 h each and finally incubated
twice in paraffin (Leica Biosystems) at 60◦C for 1 h. Heads were
mounted into wax molds and 8 μm paraffin sections were cut in
the horizontal plane and mounted onto glass slides. Three heads
of the same genotype were collected on each slide. Tissue was
visualized using the autofluorescent property of the fly brain
with a Leica DMRA2 microscope, DC500 camera, HC PLAN APO
objective lens (20× magnification and 0.70 numerical aperture)
and 1.6× tube lens, along with Leica FireCam 1.2.0 software.
Sections for quantification were imaged at the same anatomical
level of the brain, which was where the antennal nerve connects
to the antennal lobe; three adjacent sections at this anatomical
level were captured for each head. Retinal depth was measured
by drawing a line from lower edge of the retina (proximal to
the optic lamina) out toward the lens. The line drawn and
measured was always in line with the crossover point of the
optic chiasm that was visible in the optic lobe. For quantification,
three females were imaged per genotype. The experiments were
repeated three times independently. Images are presented in
reverse black and white. Retinal depth in internal eye images
was quantified using ImageJ (https://imagej.nih.gov/ij/). One-
way ANOVA and Tukey’s multiple comparisons were performed
with a significance threshold of P < 0.05.
Western immunoblots
Immunoblots on fly head tissue were performed as previously
described with minor alterations (74). Approximately 20 females
per genotype per repeat were aged on fly food for 48 h con-
taining 200 μg RU486 (Sigma-Aldrich, M8046) (100 μl of 2 mg/ml
RU486 in 200-proof ethanol). The heads from 10 female flies per
genotype were collected and homogenized in 100 μl of protein
buffer containing 100 mM Tris–HCl, pH 7.4, 1 mM EGTA, pH 8,
1× Halt protease inhibitor cocktail (Thermo Fisher, 78 430), 0.5%
sodium deoxycholate, 0.5% SDS and 1% NP-40. To each tube,
100 μl of 4× LDS sample buffer (Thermo Fisher, NP0007) with 5%
beta-mercaptoethanol. Samples were heat denatured at 95◦C for
5 min, chilled on ice for 5 min and centrifuged at 4500 × g for
5 min at 4◦C. Care was taken to pipette from the surface of the
centrifuged liquid a volume equivalent to 0.25 heads and loaded
into each well of a 4–12% Bis-Tris Protein Gel, 1.5 mm along
with 10 μl Hi-Mark Unstained Protein Standard (Thermo Fisher,
LC5688). Samples were electrophoresed for 2 h 15 min at 115 V
in NuPAGE SDS MOPS running buffer (Thermo Fisher, NP0001)
and transferred onto a 0.45 μm nitrocellulose membrane by wet
transfer in NuPAGE Transfer Buffer (Thermo Fisher, NP0006) with
10% methanol for 75 min at 30 V. The membrane was blocked in
5% non-fat milk (LabScientific, M0841) for 1 h at room temper-
ature. Membranes were incubated in mouse Ataxin-2 primary
antibody (1:600 in TBS with 0.05% Tween 20; BD Biosciences,
6 113 378) or in mouse Lamin C primary antibody (1:1000 in TBS
with 0.05% Tween 20; DSHB, LC28.26-s) at 4◦C overnight with
rocking. Membranes were washed in TBS with 0.05% Tween 20
for 5 min, 5 times, at RT with agitation and incubated with
goat anti-mouse HRP secondary antibody (1:5000 in TBS with
0.05% Tween 20, Abcam, ab6789) for 1 h at RT, with rocking.
Membranes were washed in TBS with 0.05% Tween 20 for 5 min, 5
times, at RT with agitation and incubated in ECL Prime Western
Blotting Detection Reagent (Amersham, RPN2232) for 5 min at
RT in the dark and detected by chemiluminescence using a GE
Healthcare Amersham Imager 600. Ataxin-2 band signal inten-
sity was quantified using ImageJ (https://imagej.nih.gov/ij/) and
was normalized to the signal intensity of respective Lamin C
loading control bands. One-way ANOVA and Tukey’s multiple
comparisons were performed with a significance threshold of
P < 0.05.
Cryosections
Cryosections and immunostaining were performed as previously
described (75). Adult heads of appropriate genotype were embed-
ded in O.C.T. (Tissue-Tek), 12 μm serial sections were cut and
collected on slides. Tissue was fixed in 4% paraformaldehyde
in PBS, then stained with appropriate antibodies and Hoechst
(0.5 μg/ml for 5 min). Images were scanned, using identical
parameters across genotypes, on a Leica confocal microscope.
Antibodies used were mouse anti-ATXN2 (1:200; BD611378,
BD Biosciences, Billerica, MA), rabbit anti-ATXN2 (1:200; HPA
018295, Sigma-Aldrich, St. Louis, MO), Alexa goat anti-mouse
AF568 (1:250; A11036, Invitrogen, Carlsbad, CA) and Alexa goat
anti-rabbit AF568 (1:250; A11011, Invitrogen, Carlsbad, CA).
Immunostaining with the rabbit antibodies is presented in the
figures.
Viability assays
UAS-ATXN2-CAG64 (6×), UAS-ATXN2-CAA/G65 (6×), UAS-ATXN2-
CAA64 (6×) and UAS-mCD8-GFP were crossed to either the da-
GAL4 or elav3A-GAL4 driver lines. All surviving progeny of the
expected genotypes were counted every 2 d. The ratio of the
actual numbers of the desired genotype divided by the expected
numbers of the desired genotype was calculated. The expected
numbers were based on the presumption that all genotypes were
equally likely to occur. More than 100 animals per genotype were
counted for those with regular viability.
Supplementary Material
Supplementary Material is available at HMG online.
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